Drug Trial Radar · NCT00636064
A Study Comparing the Efficacy and Safety of Valdecoxib Plus Parecoxib Versus Valdecoxib Plus Placebo for the Treatment of Pain After Coronary Artery Bypass Surgery
Last checked: Nov 20, 2026Latest source record: Oct 10, 2008 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,671
Actual
Start
Jan 2003
Primary completion
Not stated
Study completion Jan 2004
Sponsor
- Lead sponsor
- PfizerPfizer (PFE)
- Sponsor type
- Industry
- First posted
- Mar 14, 2008
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 80 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate the efficacy and safety of parecoxib/valdecoxib therapy and placebo/valdecoxib therapy for the treatment of pain after coronary artery bypass surgery
Conditions
- Pain
Interventions
Parecoxib Sodium/ValdecoxibDrug
Parecoxib sodium 40 mg intravenous (IV) on the day after surgery (Day 1) following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received parecoxib 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV parecoxib sodium, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
Placebo/ValdecoxibDrug
Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
Placebo/PlaceboOther
Patients received placebo matched to parecoxib sodium 40 mg IV on Day 1 following recovery from anesthesia, contingent on an acceptable postoperative status, verification of baseline eligibility, and lack of perioperative complications. A second dose of placebo matched to parecoxib sodium 20 mg IV was administered on Day 1. On the day following surgery, patients received placebo matched to parecoxib sodium 20 mg IV at 8 am and each subsequent dose was administered at 12-hour intervals. After receiving at least 6 doses of IV placebo, patients were transitioned to oral placebo matched to valdecoxib 20 mg taken at 12-hour intervals until the total treatment duration of 10 days had been completed.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Combined incidence of the number of patients with at least 1 confirmed clinically relevant adverse event (CRAE)Time frame: Day 30
Locations
206 sites in 27 countries. Site status is shown where the registry gives one.
Pfizer Investigational Site
Fairhope, Alabama
Pfizer Investigational Site
Mobile, Alabama
Pfizer Investigational Site
Mobile, Alabama
Pfizer Investigational Site
Mobile, Alabama
Pfizer Investigational Site
Mobile, Alabama
Pfizer Investigational Site
Tucson, Arizona
Pfizer Investigational Site
Fayetteville, Arkansas
Pfizer Investigational Site
Springdale, Arkansas
Pfizer Investigational Site
Anaheim, California
Pfizer Investigational Site
Anaheim, California
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
Los Angeles, California
Pfizer Investigational Site
Orange, California
Pfizer Investigational Site
Sacramento, California
Pfizer Investigational Site
Sacramento, California
Pfizer Investigational Site
San Francisco, California
Pfizer Investigational Site
San Francisco, California
Pfizer Investigational Site
San Francisco, California
Pfizer Investigational Site
Santa Rosa, California
Pfizer Investigational Site
Santa Rosa, California
Pfizer Investigational Site
Stanford, California
Pfizer Investigational Site
Fort Collins, Colorado
Pfizer Investigational Site
Fort Collins, Colorado
Pfizer Investigational Site
New Haven, Connecticut
Pfizer Investigational Site
New Haven, Connecticut
Pfizer Investigational Site
Washington D.C., District of Columbia
Pfizer Investigational Site
Brandon, Florida
Pfizer Investigational Site
Clearwater, Florida
Pfizer Investigational Site
Hudson, Florida
Pfizer Investigational Site
Jacksonville, Florida
Pfizer Investigational Site
Melbourne, Florida
Pfizer Investigational Site
Melbourne, Florida
Pfizer Investigational Site
Pensacola, Florida
Pfizer Investigational Site
Pensacola, Florida
Pfizer Investigational Site
Sarasota, Florida
Pfizer Investigational Site
St. Petersburg, Florida
Pfizer Investigational Site
Tampa, Florida
Pfizer Investigational Site
Atlanta, Georgia
Pfizer Investigational Site
Augusta, Georgia
Pfizer Investigational Site
Fort Wayne, Indiana
Showing 40 of 206 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.